Iguana Healthcare Management LLC increased its holdings in TESARO Inc (NASDAQ:TSRO) by 40.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 35,000 shares of the biopharmaceutical company’s stock after acquiring an additional 10,000 shares during the period. TESARO makes up about 1.9% of Iguana Healthcare Management LLC’s holdings, making the stock its 17th largest holding. Iguana Healthcare Management LLC owned approximately 0.06% of TESARO worth $2,900,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Toronto Dominion Bank boosted its position in shares of TESARO by 244.6% during the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,130 shares during the period. Commonwealth Equity Services Inc purchased a new position in shares of TESARO during the third quarter worth $222,000. Crossmark Global Holdings Inc. purchased a new position in shares of TESARO during the third quarter worth $230,000. CIBC Asset Management Inc purchased a new position in shares of TESARO during the third quarter worth $234,000. Finally, Exane Derivatives boosted its position in shares of TESARO by 137.1% during the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 1,123 shares during the period.
In other TESARO news, VP Grant C. Bogle sold 1,809 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $54.85, for a total value of $99,223.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Timothy R. Pearson sold 2,575 shares of the firm’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $54.86, for a total value of $141,264.50. Following the completion of the sale, the chief financial officer now owns 7,303 shares in the company, valued at $400,642.58. The disclosure for this sale can be found here. Over the last 90 days, insiders acquired 334,913 shares of company stock worth $19,083,294 and sold 13,042 shares worth $760,526. 34.60% of the stock is owned by company insiders.
Shares of TESARO stock opened at $61.81 on Monday. The stock has a market capitalization of $3,372.60, a price-to-earnings ratio of -6.73 and a beta of 1.40. The company has a quick ratio of 4.39, a current ratio of 4.74 and a debt-to-equity ratio of 1.75. TESARO Inc has a 52 week low of $52.20 and a 52 week high of $168.92.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.39) by ($0.96). TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. The company had revenue of $48.02 million during the quarter, compared to analyst estimates of $51.78 million. analysts anticipate that TESARO Inc will post -9.54 EPS for the current year.
Several research analysts have recently commented on the company. Piper Jaffray Companies restated a “hold” rating and set a $65.00 price target on shares of TESARO in a research report on Thursday, January 18th. Wells Fargo restated an “outperform” rating and set a $122.00 price target (down from $224.00) on shares of TESARO in a research report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and set a $158.00 price target on shares of TESARO in a research report on Monday, November 20th. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. Finally, Royal Bank of Canada lowered their price target on TESARO to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $133.39.
ILLEGAL ACTIVITY NOTICE: “Iguana Healthcare Management LLC Has $2.90 Million Position in TESARO Inc (TSRO)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/19/iguana-healthcare-management-llc-has-2-90-million-position-in-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.